Hims goes flat as EU acquisition excitement fades
Hims & Hers health gave up all its gains after rising more than 17% in early trading following its announcement that it would carry out its international expansion promises and acquire a European peer, Zava.
Zava and Hims provide most of the same services, but Zava does not offer compounded or “personalized” regimens like Hims does, analysts at Citibank pointed out in a note. Those products are branded and higher-margin than generics.
Zava’s parent company, Health Bridge Limited, was not profitable as recently as 2023, when it reported to UK regulators that it turned a net loss of £321,902, less than the £8.3 million it lost a year earlier. Hims also did not report a full profitable year until 2024.
Zava’s parent company, Health Bridge Limited, was not profitable as recently as 2023, when it reported to UK regulators that it turned a net loss of £321,902, less than the £8.3 million it lost a year earlier. Hims also did not report a full profitable year until 2024.
